CSIMarket
 


Chemocentryx Inc.  (CCXI)
Other Ticker:  
 
 

CCXI's Capital Expenditures Growth by Quarter and Year

Chemocentryx's Capital Expenditures results by quarter and year




CCXI Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 0.49 4.01 0.23
III Quarter September - 4.35 1.26 0.19
II Quarter June 0.40 3.30 0.87 0.05
I Quarter March 0.22 10.88 0.33 0.08
FY   0.62 19.02 6.47 0.55



CCXI Capital Expenditures second quarter 2022 Y/Y Growth Comment
Chemocentryx Inc. reported drop in Capital Expenditures in the second quarter 2022 by -87.76% to $ 0.40 millions, from the same quarter in 2021.
The fall in the second quarter 2022 Chemocentryx Inc.'s Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 269.93%.

Looking into second quarter 2022 results within Major Pharmaceutical Preparations industry 263 other companies have achieved higher Capital Expenditures growth. While Chemocentryx Inc.' s Capital Expenditures meltdown of -87.76% ranks overall at the positon no. 3298 in the second quarter 2022.




CCXI Capital Expenditures ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - -87.78 % 1643.48 % 91.67 %
III Quarter September - 245.24 % 563.16 % -68.33 %
II Quarter June -87.76 % 279.31 % 1640 % 66.67 %
I Quarter March -97.98 % 3196.97 % 312.5 % -77.14 %
FY   - 193.97 % 1076.36 % -50 %

Financial Statements
Chemocentryx's second quarter 2022 Capital Expenditures $ 0.40 millions CCXI's Income Statement
Chemocentryx's second quarter 2021 Capital Expenditures $ 3.30 millions Quarterly CCXI's Income Statement
New: More CCXI's historic Capital Expenditures Growth >>


CCXI Capital Expenditures (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -88.74 % 218.25 % 21.05 %
III Quarter September - 31.82 % 44.83 % 280 %
II Quarter June 83.64 % -69.67 % 163.64 % -37.5 %
I Quarter March -55.1 % 171.32 % 43.48 % -33.33 %
FY (Year on Year)   - 193.97 % 1076.36 % -50 %




Capital Expenditures second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #264
Healthcare Sector #636
Overall #3298

Capital Expenditures Y/Y Growth Statistics
High Average Low
1786.96 % 269.93 % -97.94 %
(Mar 31 2020)   (Mar 31 2022)
Capital Expenditures second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #264
Healthcare Sector #636
Overall #3298
Capital Expenditures Y/Y Growth Statistics
High Average Low
1786.96 % 269.93 % -97.94 %
(Mar 31 2020)   (Mar 31 2022)

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Chemocentryx's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
1771.88 % 90.29 % -100 %
(Jun 30 2018)  


CCXI's II. Quarter Q/Q Capital Expenditures Comment
Chemocentryx Inc. achieved in the II. Quarter 2022 below company average Capital Expenditures jump of 83.64% quarter on quarter, to $ 0.40 millions.

Even if the II. Quarter 2022 Chemocentryx's performance was beneath the ordinary , it has been still encouraging sign, as the II. Quarter improvement, outshines the -69.67% surge in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Chemocentryx's Capital Expenditures growth quarter on quarter, overall rank is 350.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #84
Overall #350
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #84
Overall #350
Capital Expenditures Q/Q Growth Statistics
High Average Low
1771.88 % 90.29 % -100 %
(Jun 30 2018)  


CCXI's II. Quarter Q/Q Capital Expenditures Comment
Chemocentryx Inc. achieved in the II. Quarter 2022 below company average Capital Expenditures jump of 83.64% quarter on quarter, to $ 0.40 millions.

Albeit the II. Quarter 2022 Chemocentryx's Capital Expenditures quarter on quarter growth was beneath the average , that has been yet good news, as the current expension, eclipses the -69.67% Capital Expenditures rise in the same quarter a year ago

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Chemocentryx's Capital Expenditures growth quarter on quarter, overall rank is 350.


Chemocentryx's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
Cumulative Capital Expenditures 12 Months Ending $ 5.47 $ 8.36 $ 19.02 $ 22.53 $ 19.45
Y / Y Capital Expenditures Growth (TTM) -71.86 % -50.85 % 194.38 % 739.53 % 1106.27 %
Year on Year Capital Expenditures Growth Overall Ranking # 2325 # 2766 # 176 # 70 # 45
Seqeuential Capital Expenditures Change (TTM) -34.59 % -56.03 % -15.59 % 15.88 % 14.27 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1965 # 3297 # 1804 # 983 # 952




Cumulative Capital Expenditures growth Comment
Chemocentryx's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -71.86% year on year, at Jun 30 2022 compare to the -50.85% decrease at Mar 31 2022. If the Chemocentryx's fiscal year would end at Jun 30 2022, annual Capital Expenditures would be $5 millions.

In the Healthcare sector 390 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 2325, from total ranking in previous quarter at 2766.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
163.36 %
22.18 %
-56.03 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 95
Healthcare Sector # 391
Overall # 2325

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
2053.92 %
297.76 %
-71.86 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 95
Sector # 308
S&P 500 # 1965
Cumulative Capital Expenditures growth Comment
Chemocentryx's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -71.86% year on year, at Jun 30 2022 compare to the -50.85% decrease at Mar 31 2022. If the Chemocentryx's fiscal year would end at Jun 30 2022, annual Capital Expenditures would be $5 millions.

In the Healthcare sector 390 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 2325, from total ranking in previous quarter at 2766.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
163.36 %
22.18 %
-56.03 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 95
Healthcare Sector # 391
Overall # 2325

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
2053.92 %
297.76 %
-71.86 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 95
Sector # 308
S&P 500 # 1965




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
CCXI's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for CCXI's Competitors
Capital Expenditures Growth for Chemocentryx's Suppliers
Capital Expenditures Growth for CCXI's Customers

You may also want to know
CCXI's Annual Growth Rates CCXI's Profitability Ratios CCXI's Asset Turnover Ratio CCXI's Dividend Growth
CCXI's Roe CCXI's Valuation Ratios CCXI's Financial Strength Ratios CCXI's Dividend Payout Ratio
CCXI's Roa CCXI's Inventory Turnover Ratio CCXI's Growth Rates CCXI's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Jun 30 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Jun 30 2022
Novan Inc -0.21%$ -0.213 millions
Endo International Plc-0.32%$ -0.317 millions
Molecular Templates inc -0.59%$ -0.590 millions
Atricure Inc -0.69%$ -0.688 millions
Seagen Inc -0.83%$ -0.833 millions
Boston Scientific Corporation-0.94%$ -0.943 millions
Ispecimen inc -1.10%$ -1.098 millions
3m Company-2.54%$ -2.538 millions
Eli Lilly And Company-2.70%$ -2.701 millions
Dynatronics Corporation-2.88%$ -2.878 millions
Amicus Therapeutics inc -3.01%$ -3.005 millions
Hanger inc.-3.02%$ -3.016 millions
Encompass Health Corporation-3.39%$ -3.390 millions
Surmodics Inc-4.44%$ -4.440 millions
Davita Inc -4.80%$ -4.797 millions
Tenaya Therapeutics Inc -5.07%$ -5.067 millions
Abiomed Inc -5.40%$ -5.397 millions
Healthcare Services Group Inc -5.63%$ -5.632 millions
Cidara Therapeutics Inc -5.88%$ -5.882 millions
Viatris Inc -6.05%$ -6.047 millions
Mimedx Group Inc -6.17%$ -6.173 millions
Vericel Corporation-6.47%$ -6.468 millions
Caremax Inc -6.61%$ -6.614 millions
Sight Sciences Inc -7.32%$ -7.317 millions
Abbott Laboratories-8.23%$ -8.232 millions
National Healthcare Corp-8.45%$ -8.451 millions
1life Healthcare Inc -8.56%$ -8.561 millions
Urogen Pharma Ltd -8.70%$ -8.696 millions
F star Therapeutics Inc -8.95%$ -8.951 millions
Becton Dickinson And Company-8.99%$ -8.989 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com